AMT-253 ADC
/ Multitude Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 05, 2023
A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma
(Clin Cancer Res)
- "AMT-253 exhibited MUC18-specific cytotoxicity through DNA damage and apoptosis and a strong bystander killing effect, leading to potent antitumor activities against melanoma cell line and patient-derived xenograft models. Tumor vasculature-targeting by a mouse MUC18-specific antibody-T1000-exatecan conjugate inhibited tumor growth in human melanoma xenografts."
Preclinical • Melanoma
1 to 1
Of
1
Go to page
1